Gabrielle Union's Fertility Journey: What It Would Real Cost a Non-Celebrity

What Gabrielle Union Actually Said About Her Fertility

Gabrielle Union has been remarkably specific in public forums, and that specificity is what makes her story worth examining clinically. She is not a vague celebrity who "struggled with fertility." She has named the diagnosis, named the number of failures, and described the emotional cost in detail.

In her 2017 memoir We're Going to Need More Wine and in subsequent interviews, Union disclosed that she was diagnosed with adenomyosis, a condition in which the tissue that normally lines the uterus grows into the muscular wall of the uterus itself. She has stated that doctors told her it was "one of the worst cases they had ever seen." In a 2019 interview with People, she described undergoing "eight or nine" embryo transfers before pursuing gestational surrogacy. Her daughter, Kaavia James Union Wade, was born in November 2018 via a gestational surrogate.

These are primary disclosures from Union herself. Where this article draws clinical inference, that inference is labeled.

What Is Adenomyosis and Why Does It Complicate Fertility?

Adenomyosis is distinct from endometriosis, though the two conditions can coexist. In adenomyosis, uterine glands and stroma invade the myometrium, causing the uterus to enlarge, the muscular wall to thicken, and the uterine environment to become hostile to embryo implantation. Research published in Human Reproduction Update found that adenomyosis is associated with a significantly lower clinical pregnancy rate and live birth rate in IVF cycles compared to controls, with live birth rates reduced by roughly 28 percent.

The condition disproportionately affects women in their 30s and 40s, which overlaps precisely with the period when many women are actively trying to conceive. Diagnosis is typically made by transvaginal ultrasound or MRI, not by laparoscopy (unlike endometriosis). Because adenomyosis is embedded in the uterine muscle, it cannot be surgically removed without removing the uterus itself in most cases, which is why gestational surrogacy becomes a genuine clinical option rather than a last resort in severe cases.

ACOG has acknowledged adenomyosis as a real contributor to infertility and recurrent pregnancy loss, though guideline-level evidence specifically on adenomyosis-related infertility management remains thinner than clinicians would like. This is an area where the evidence gap for women is real and worth naming.

The Recurrent Implantation Failure Picture

Eight to nine failed embryo transfers places Union in the category of recurrent implantation failure (RIF), generally defined as failure to achieve a clinical pregnancy after transfer of at least three good-quality embryos. A 2021 consensus statement from the ESHRE (European Society of Human Reproduction and Embryology) defined RIF as failure to achieve clinical pregnancy after transfer of at least three euploid embryos of good quality in a minimum of three fresh or frozen cycles. The workup for RIF typically includes uterine cavity assessment, thrombophilia screening, immunological testing, and, increasingly, endometrial receptivity analysis.

For a woman with adenomyosis and RIF, the clinical conversation eventually turns toward whether her uterus can sustain a pregnancy at all. That is the conversation Union appears to have had.

What Each Stage of Her Path Would Cost a Non-Celebrity

This is where the celebrity framing matters most. Union's resources, and her husband Dwyane Wade's NBA earnings, are not available to most women. Here is what the same clinical path would realistically cost in the United States today.

Diagnosis: Adenomyosis Workup

Before any fertility treatment begins, you need a diagnosis. An initial fertility workup for a woman presenting with heavy periods, pelvic pain, and difficulty conceiving includes:

• Transvaginal ultrasound: $200 to $500 out-of-pocket if not covered
• Pelvic MRI (more sensitive for adenomyosis): $500 to $2,000 depending on facility and insurance
• Hysteroscopy to assess the uterine cavity: $1,500 to $4,000
• Hormonal panel (FSH, estradiol, AMH, LH, thyroid): $200 to $600

Total diagnostic phase: $2,400 to $7,100, much of which may be covered under gynecology benefits rather than the fertility carve-out, though that depends heavily on your plan.

IVF: The Cost Per Cycle

A single IVF cycle in the U.S. Typically costs $12,000 to $17,000 in base fees, but that number is misleading. Add medications (injectable gonadotropins and progesterone support), which run $3,000 to $8,000 per cycle, and the real cost per attempt is closer to $15,000 to $25,000. If preimplantation genetic testing for aneuploidy (PGT-A) is included, add another $3,000 to $6,000.

The American Society for Reproductive Medicine's 2023 data indicates that the average cost of one IVF cycle in the U.S. Exceeds $23,000 when medications and monitoring are included.

Eight to nine transfers, even assuming embryos were banked across fewer egg retrieval cycles, represents a staggering financial commitment. If Union underwent four egg retrieval cycles and five to six frozen embryo transfers, a reasonable clinical reconstruction, the medication and procedure costs alone would exceed $80,000 to $120,000 before surrogacy.

What Fertility Medications Would She Have Taken?

This section uses clinical inference, clearly labeled as such, since Union has not publicly detailed her specific protocol.

For ovarian stimulation (egg retrieval), women with adenomyosis typically receive:

• Gonadotropins (FSH-based injectables such as Gonal-F or Menopur): stimulate multiple follicle development. Doses range from 150 to 450 IU daily for 8 to 14 days.
• GnRH antagonist (cetrorelix or ganirelix): prevents premature ovulation during stimulation.
• HCG or GnRH agonist trigger: matures the eggs for retrieval.

For frozen embryo transfer cycles, the standard protocol includes:

• Estradiol (oral or transdermal patches): builds the uterine lining
• Progesterone (vaginal suppositories or intramuscular injections): supports implantation

Women with adenomyosis may also be placed on a GnRH agonist suppression protocol (leuprolide acetate, brand name Lupron) for one to three months before transfer to reduce adenomyosis activity and improve endometrial receptivity. A 2019 meta-analysis in Fertility and Sterility found that GnRH agonist pre-treatment before IVF in women with adenomyosis significantly improved clinical pregnancy rates compared to no pre-treatment. This adds another $500 to $1,500 per suppression cycle in medication costs.

Does Gabrielle Union Take Fertility Medication?

This is one of the most commonly searched questions about her fertility journey. The direct answer: Union has not publicly specified which fertility drugs she took by name. Given her disclosed diagnosis of adenomyosis and the number of IVF transfers she described, standard clinical practice would have included the medications above. Inferring a specific named protocol without her confirmation would be speculation. What is clinically certain is that any woman undergoing multiple IVF cycles and frozen embryo transfers in her late 30s and early 40s would have received injectable gonadotropins, progesterone support, and likely GnRH agonist suppression given the adenomyosis diagnosis.

Insurance: The Coverage Lottery

As of 2025, only 21 states have enacted fertility insurance mandates, and the scope of those mandates varies enormously. Some cover only diagnosis. Some require IVF coverage only for women under 40 or only for those who have been trying for 24 months. Employer self-funded plans are exempt from state mandates under ERISA, meaning that even women in mandate states may have no coverage if their employer self-insures.

A woman going through eight to nine transfers in a non-mandate state, or in a state with limited coverage, could easily spend $150,000 to $200,000 out of pocket on IVF alone, not including surrogacy.

Gestational Surrogacy: The Real Financial Ceiling

Gestational surrogacy in the United States is the most expensive reproductive option available. The cost breakdown for a non-celebrity is approximately:

| Line item | Estimated cost | |---|---| | Surrogate compensation | $35,000 to $60,000 | | Agency fee | $20,000 to $30,000 | | Legal fees (both parties) | $10,000 to $20,000 | | Medical fees (surrogate's IVF transfer and prenatal care) | $20,000 to $40,000 | | Psychological screening and counseling | $2,000 to $5,000 | | Insurance for surrogate | $10,000 to $30,000 | | Total | $97,000 to $185,000 |

This assumes embryos already exist from the intended mother's prior IVF cycles. If new embryo creation is needed, add another retrieval cycle cost on top.

A 2022 report from the Society for Assisted Reproductive Technology noted that gestational surrogacy arrangements in the U.S. Have increased substantially over the past decade, but access remains sharply stratified by income.

Adenomyosis and Fertility: The Clinical Picture Most Articles Skip

Most celebrity fertility articles stop at "she did IVF and surrogacy." This section offers a framework for understanding adenomyosis as a fertility-limiting diagnosis in clinical terms, because the diagnosis itself shapes every treatment decision that follows.

How Adenomyosis Affects Implantation

The proposed mechanisms by which adenomyosis impairs fertility include:

1. Altered uterine contractility. The infiltrated myometrium contracts abnormally, which may expel embryos or prevent proper implantation.
2. Impaired endometrial receptivity. Gene expression studies have found that women with adenomyosis show altered expression of implantation markers including HOXA10, integrin beta-3, and LIF (leukemia inhibitory factor) during the window of implantation. A study in Fertility and Sterility confirmed reduced HOXA10 and beta-3 integrin expression in adenomyosis endometrium.
3. Toxic uterine environment. Elevated reactive oxygen species and altered cytokine profiles in the adenomyotic uterus may be directly embryotoxic.

Why the Uterus Cannot Always Be "Fixed"

Unlike fibroids, which can often be removed while preserving fertility, adenomyosis embedded diffusely in the myometrium cannot be excised surgically without removing the uterus (hysterectomy). Focal adenomyomas, a localized form, can sometimes be resected, but diffuse disease, particularly severe cases like the one Union described, is not amenable to surgical cure while maintaining fertility. This is why gestational surrogacy represents a genuine clinical endpoint rather than a choice made for convenience.

What the GnRH Agonist Suppression Protocol Looks Like

For women with adenomyosis undergoing IVF, many reproductive endocrinologists now recommend a period of GnRH agonist suppression (typically with leuprolide acetate 3.75 mg monthly injections or 11.25 mg every three months) before embryo transfer. This creates a temporary menopausal state, shrinks the adenomyotic tissue, and may improve endometrial receptivity for the transfer cycle. Side effects include hot flashes, night sweats, vaginal dryness, and temporary bone density loss with extended use, which is why the duration is kept as short as clinically needed.

Life Stage Considerations: How Age Changes the Picture

Gabrielle Union was in her mid-to-late 30s during most of her IVF attempts and 45 when Kaavia James was born via surrogate in 2018. Age is a central variable in fertility treatment outcomes.

In Your Reproductive Years (Under 35)

Women under 35 with adenomyosis may still have adequate ovarian reserve (as measured by AMH and antral follicle count), and IVF outcomes, while still compromised by adenomyosis, are better than in older age groups. Live birth rates per egg retrieval cycle for women under 35 average approximately 40 to 50 percent nationally, per SART 2022 data, though adenomyosis reduces this meaningfully.

Trying to Conceive After 35

Ovarian reserve declines with age, so egg quantity and quality both fall. After 35, the conversation about PGT-A (preimplantation genetic testing) becomes more urgent because chromosomal abnormalities in embryos rise sharply. By age 40, approximately 50 to 60 percent of embryos may be aneuploid, meaning untested embryo transfer has a substantially higher failure rate. Adding PGT-A increases per-cycle costs but may reduce the number of failed transfers over time.

Perimenopause and Beyond

Women in perimenopause, typically beginning in the mid-40s, face declining ovarian reserve alongside fluctuating estrogen and progesterone. IVF with own eggs becomes substantially less successful. SART data shows live birth rates per retrieval cycle drop to approximately 3 to 5 percent for women over 42 using their own eggs. Egg donation or embryo donation becomes the more realistic path to pregnancy for many women at this stage, though gestational surrogacy can be combined with either approach.

Union's story spans this transition. The embryos transferred may have been created at a younger age, which is a clinically relevant detail, though she has not publicly confirmed this.

Pregnancy and Lactation Safety: Fertility Medications

This section covers the medications typically used in an IVF cycle relevant to Union's described treatment path.

Gonadotropins (Gonal-F, Menopur, Follistim)

These injectable medications are used during ovarian stimulation, before pregnancy. They are discontinued at or before egg retrieval and are not used during pregnancy. They carry no direct fetal risk because they are not taken once a pregnancy is established.

Progesterone Supplementation

Vaginal progesterone (Crinone, Endometrin) and intramuscular progesterone are routinely continued through the first trimester of an IVF pregnancy to support the luteal phase. FDA labeling for vaginal progesterone gel (Crinone) designates it Pregnancy Category B based on available data, meaning animal studies showed no fetal risk and adequate human studies have not demonstrated a risk. Progesterone does transfer into breast milk but at low levels; most reproductive endocrinologists discontinue it well before delivery, making lactation exposure moot in most protocols.

Leuprolide Acetate (Lupron) for Pre-Transfer Suppression

Lupron is used only in the pre-treatment phase, before embryo transfer and before any pregnancy. It is contraindicated in established pregnancy and carries an FDA Pregnancy Category X designation based on animal data showing fetal harm and the absence of a clinical justification for use during pregnancy. The FDA prescribing information for leuprolide acetate states it should not be used in women who are or may become pregnant. Women must use reliable contraception if sexually active during Lupron suppression cycles, even though the drug itself is suppressing ovulation, because the risk of inadvertent fetal exposure to GnRH agonists is a genuine concern.

Lupron is not used during pregnancy and is discontinued before embryo transfer. Lactation transfer data is limited, and use during breastfeeding is not recommended.

A Note on Gestational Surrogacy and Medication Use by the Intended Mother

In a gestational surrogacy arrangement, the surrogate (not the intended mother) carries the pregnancy. The intended mother's role ends at embryo creation, unless a fresh transfer cycle is used. This means the intended mother does not face medication-in-pregnancy risks related to the surrogate's pregnancy. The surrogate has her own separate medication protocol (estrogen and progesterone for endometrial preparation) and her own informed consent process.

Who This Path Is Right For, and Who It Is Not

Women for Whom This Applies Most Directly

• Women with a confirmed adenomyosis diagnosis who have not been able to conceive after 6 to 12 months of trying
• Women with recurrent implantation failure (three or more failed embryo transfers) who have not had a complete RIF workup including endometrial receptivity analysis
• Women over 38 who are trying to conceive and have not yet assessed their ovarian reserve (AMH level, antral follicle count)
• Women who have been told they need a hysterectomy for adenomyosis but have not yet completed their family, and have not been offered the option of embryo banking before surgery

Women for Whom Immediate IVF or Surrogacy May Not Be the First Step

• Women under 35 with mild adenomyosis who have been trying for fewer than 12 months: a structured attempt with cycle monitoring and, if appropriate, intrauterine insemination may be reasonable before moving to IVF
• Women who have not yet had a full adenomyosis diagnosis confirmed by MRI, where "suspected adenomyosis" on ultrasound has not been fully characterized
• Women who have significant financial constraints and have not yet explored state fertility insurance mandates, fertility financing programs, or clinical trial participation for reduced-cost IVF

The Honest Affordability Verdict

The total cost of Gabrielle Union's described fertility path, eight to nine IVF transfers followed by gestational surrogacy, would be $150,000 to $300,000 or more for a woman without celebrity income or exceptional employer fertility benefits. That figure is not a scare tactic. It is a realistic range drawn from current ASRM, SART, and agency cost data.

For context, the median U.S. Household income in 2023 was approximately $74,580 per year, per the U.S. Census Bureau. The cost of Union's fertility path represents two to four years of median pre-tax household income, before housing, food, or any other expense. This disparity is why advocacy organizations including RESOLVE: The National Infertility Association have called for expanded fertility insurance mandates and why the fertility access gap along income lines is one of the more significant women's-health equity issues in reproductive medicine today.

ACOG's Committee Opinion on access to fertility services states directly that "financial barriers to fertility treatment disproportionately affect women of lower socioeconomic status, women of color, and single women".

Practical Steps If You Recognize Your Own Story in Hers

If Union's experience sounds familiar, here are the concrete next steps a clinician would recommend.

Get an AMH test and antral follicle count. This tells you where your ovarian reserve stands right now. AMH can be drawn on any day of your cycle. A result below 1.0 ng/mL warrants a prompt reproductive endocrinology referral.

Request a pelvic MRI if adenomyosis is suspected. Transvaginal ultrasound can miss or undercharacterize adenomyosis. An MRI gives a more complete picture of the extent of myometrial involvement.

Check your state's fertility insurance mandate status. RESOLVE maintains an updated state-by-state map. Even partial coverage can reduce out-of-pocket burden significantly.

Ask your RE about GnRH agonist pre-treatment if you have adenomyosis and prior failed transfers. The evidence supporting a suppression protocol before transfer, while not from a large randomized trial, is consistent enough that most reproductive endocrinologists now offer it.

Consult a reproductive attorney before any surrogacy exploration. Surrogacy law varies by state, and the legal framework established before a surrogate is matched protects everyone involved.